07:32 AM EDT, 10/29/2025 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) reported a Q3 loss Wednesday of $0.80 per diluted share, narrowing from a loss of $0.95 a year earlier.

Analysts polled by FactSet expected a loss of $1.22..

Revenue for the quarter ended Sept. 30 was $157 million, compared with $134 million a year earlier.

Analysts surveyed by FactSet expected $130.3 million.

For 2025, the company now expects revenue of between $875 million and $900 million, compared with its prior outlook of $825 million and $850 million. Analysts polled by FactSet expect $866.7 million.